-
Enrollment Complete for Levosimendan’s REFALS Trial in ALS
Orion announced that the REFALS Phase 3 trial has completed its target enrollment to explore the beneficial effects of levosimendan in ALS patients. Read more about it here.
How do you feel about this news?
Sorry, there were no replies found.
Log in to reply.